The report “Human
Insulin Market - Drugs
(Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands
(Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes),
Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020” The Global Human Insulin Market Is Poised to reach
~USD 39.13 Billion by 2020, growing at a CAGR of 8.1% from 2015 to 2020 and
studies the global human insulin market over the forecast period of 2015 to
2020.
Browse 75 market tables and 53 figures spread
through 157 pages and in-depth TOC on "Human Insulin Market”
http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html
Early buyers will receive 10% customization on This reports.
Market growth can be attributed to factors such as growing
diabetes patient population, increasing population exposure to key risk factors
leading to diabetes, rising market demand for human insulin analogs,
technological advancements in the field of human insulin delivery devices, and
favorable medical reimbursements. However, stringent regulatory requirements
for product approval are restraining the growth of market. In addition, high
product manufacturing costs is posing significant challenges for market growth.
On the basis of product, the human
insulin market is classified into two major segments— drugs and delivery
devices. Human insulin drugs segment is expected to account for the largest
share of the global market, by product, in 2015. Its large share is propelled
by factors such as increasing diabetic population across globe, growing R&D
for drug discovery & development, rising proportion of aging population in
developed countries, increasing market accessibility of generic human insulin
products worldwide, and rising government initiatives to support the
development and commercialization of effective biosimilars.
On the basis of product type, the human insulin delivery devices
market is classified into three segments—pens, pen needles, and syringes. The
pens segment is expected to account for the largest market share in 2015; it is
poised to be the fastest-growing segment during the next five years. Its high
growth can be attributed to growing market focus of pen manufacturers on emerging
countries such as China, India, & Brazil; significant medical
reimbursements offered for human insulin pens across mature markets such as the
U.S. & Europe; and continuous pipeline development & product
commercialization of innovative human insulin pens.
The Sample Report For This Report@
Geographically, the market is classified into four regions—North
America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North
America is estimated to dominate the global human insulin market. The
Asia-Pacific market is poised to grow the fastest, during the forecast period,
owing to growing diabetes prevalence in APAC (coupled with large diabetic &
pre-diabetic patient population), strengthening distribution networks of global
product manufacturers in the region, evolving regulatory framework for
marketing approvals & medical reimbursements, continued expansion of advanced
medical facilities in emerging countries (such as China & India), and
rising public awareness related to benefits offered by human insulin in
diabetes treatment.
Geography expansion and product development are the key strategies
adopted by major players to strengthen their positions in the global market.
Moreover, strategies such as partnerships, agreements, collaborations,
awareness campaigns, and research funding & grants were also adopted by a
significant number of market players to strengthen their product portfolios and
expand their distribution networks in the global human insulin market.
Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company
(U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland),
Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen
AG (Switzerland), and Biodel Inc. (U.S.) are few of the key players operating
in the global human insulin market.
Get The PDF Brochure For This Report@
About MarketsandMarkets™:
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies’
revenues. Currently servicing 5000 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our
850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high
growth markets following the "Growth Engagement Model – GEM". The GEM
aims at proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their innovations/disruptions
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche
markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701
Pike Street
Suite
2175, Seattle,
WA
98101, United States
Tel:
1-888-600-6441
No comments:
Post a Comment